In North America, more than 2 million people suffer from these debilitating conditions.
More than 40% of IBD patients do not tolerate or respond well to current therapies. Currently available medications alleviate inflammation but do not prevent long-term complications. There is a strong need to broaden the therapeutic arsenal with novel, orally-administered therapeutic modalities, which could become alternatives to biologic medications.
The primary indication targeted by giiant is moderate-to-severe, active ulcerative colitis. giiant’s lead compound GT-2108 is a gut-restricted, colon-specific PDE4 prodrug inhibitor. GT-1908 is also a gut-restricted PDE4 inhibitor prodrug able to deliver the active drug more proximally, making it a suitable candidate for the treatment of Crohn’s disease.
Table of pipeline
|Drug candidate||target||Gut-restricted||Tissue Specific||discovery||preclinical||phase 1||phase 2||phase 3|
Drug Hunting Club
giiant pharma is continually looking for new GI-related technologies. giiant created a Drug Hunting Club to identify new, promising opportunities to in-license. If you have a technology to propose that is aligned with our lead asset GT-2108, please contact us.